FMR LLC reports 6.8% stake in Arrivent Biopharma

Arrivent Biopharma Inc ownership update: FMR LLC reports beneficial ownership of 3,016,131.87 shares of Common Stock, representing 6.8% of the class as disclosed on the cover information.

Rhea-AI Filing Summary

Arrivent Biopharma Inc ownership update: FMR LLC reports beneficial ownership of 3,016,131.87 shares of Common Stock, representing 6.8% of the class as disclosed on the cover information. The filing states voting and dispositive powers held by FMR LLC and identifies Abigail P. Johnson with dispositive power over the same shares.

The filing is an amendment to a Schedule 13G/A and includes Exhibit 99 and a power of attorney reference.

Insights

Institutional Ownership Analyst

Large passive-holder update: FMR LLC reports a 6.8% stake in Arrivent Biopharma.

FMR LLC is reported to beneficially own 3,016,131.87 shares and to hold sole dispositive power for that amount. The disclosure lists Abigail P. Johnson as having dispositive power through the filing structure.

Because this is a Schedule 13G/A amendment, it reflects beneficial-ownership reporting rather than a transaction; timing and cash-flow treatment are not specified in the excerpt.

Key Figures

Beneficial ownership: 3,016,131.87 shares Percent of class: 6.8% CUSIP: 04272N102 +2 more

5 metrics

Beneficial ownership 3,016,131.87 shares Amount beneficially owned reported in Item 4

Percent of class 6.8% Percent of common stock as reported in Item 4

CUSIP 04272N102 Issuer CUSIP on cover information

Filing date (cover) 03/31/2026 Date shown near header information

Signature date 05/05/2026 Dates of signatures for the amendment

Key Terms

Schedule 13G/A, beneficial ownership, dispositive power, 13d-1(k)(1) agreement

4 terms

Schedule 13G/A regulatory

"Amendment No. 2 ) ARRIVENT BIOPHARMA INC ... SCHEDULE 13G/A"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial ownership financial

"Item 4. | Ownership (a) | Amount beneficially owned: 3016131.87"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

dispositive power regulatory

"7 | Sole Dispositive Power 3,016,131.87 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

13d-1(k)(1) agreement regulatory

"Exhibit Information Please see Exhibit 99 for 13d-1(k) (1) agreement."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does FMR LLC report in Arrivent Biopharma (AVBP)?

FMR LLC reports beneficially owning 3,016,131.87 shares, equal to 6.8% of Arrivent Biopharma's common stock. This figure and percentage are presented in the Schedule 13G/A amendment's Item 4 ownership section on the cover information.

Who is named with dispositive power over AVBP shares in the filing?

The filing lists FMR LLC as having sole dispositive power for 3,016,131.87 shares and identifies Abigail P. Johnson as having dispositive power in the filing's cover responses.

What form and exhibits accompany the AVBP ownership disclosure?

The disclosure is an amended Schedule 13G/A (Amendment No. 2) and references Exhibit 99 for a 13d-1(k)(1) agreement and a power of attorney incorporated by reference to Exhibit 24 in an earlier filing.

Does the filing state if any other person holds more than 5% of AVBP?

The filing states that one or more other persons have rights to dividends or sale proceeds but that no other single person is known to have an interest exceeding 5% of the outstanding common stock, per Item 6.

What is the issuer and CUSIP listed in the amendment?

The issuer is listed as Arrivent Biopharma Inc and the CUSIP provided on the cover is 04272N102, as shown in the filing header information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 11:00 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

ARRIVENT BIOPHARMA INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

04272N102

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 04272N102

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,010,803.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,016,131.87
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,016,131.87

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 04272N102

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,016,131.87
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,016,131.87

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ARRIVENT BIOPHARMA INC
(b)	Address of issuer's principal executive offices: 18 CAMPUS BLVD,SUITE 100,NEWTOWN SQUARE,PA,USA,19073-3269
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 04272N102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3016131.87
(b)	Percent of class: 6.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 3016131.87
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ARRIVENT BIOPHARMA INC. No one other person's interest in the COMMON STOCK of ARRIVENT BIOPHARMA INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	05/05/2026

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:	05/05/2026

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.